Osta BE, Carlisle J, Steuer C, Pakkala S, et al. A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non-Small-Cell Lung Cancer (NSCLC) who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade. Clin Lung Cancer 2022 Jun 22. pii: S1525-7304(22)00147.
PMID: 35863963